A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2001
11/08/2001	WO2001017516A3 Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
11/08/2001	WO2001010846A3 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
11/08/2001	WO2001008707A3 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
11/08/2001	WO2000076556A9 High dose radionuclide complexes for bone marrow suppression
11/08/2001	WO2000074666A3 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
11/08/2001	WO2000053745A9 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
11/08/2001	WO2000051644A8 TREATMENT OF DIARRHEA CAUSED BY ENTEROPATHOGENIC $i(ESCHERICHIA COLI)
11/08/2001	WO2000051566A9 Scar reduction
11/08/2001	WO2000041683A3 Transdermal therapeutic system with self-adhesive matrix, containing organic acid addition salts of morphine- or morphinan-type alkaloids
11/08/2001	WO2000033888A3 Prodrug compounds and process for preparation thereof
11/08/2001	WO2000017133A3 Lta4 hydrolase inhibitors
11/08/2001	US20010039452 Spine distraction implant and method
11/08/2001	US20010039438 Method for treating neovascularization
11/08/2001	US20010039414 Sustained release delivery systems for solutes
11/08/2001	US20010039411 Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same
11/08/2001	US20010039352 Production method of isoxazolidinedione compound
11/08/2001	US20010039350 Suitable for prophylaxis of diseases involving interleukin-1 beta such as septic shock, leukemia, hepatits, muscular degeneration, HIV infections, or degenerative joint diseases
11/08/2001	US20010039348 Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group
11/08/2001	US20010039347 Heating a mixture of caprolactone and p-methoxybenzylamine; cyclization
11/08/2001	US20010039344 Antidiabetic agents
11/08/2001	US20010039343 Pesticides, fungicides, herbicides, insecticides, microbiocdes, drugs
11/08/2001	US20010039333 Reacting with methanesulfonic acid; neutralization; crystallization
11/08/2001	US20010039297 Compositions and method for improving insulin sensivity and glucose metabolism in individuals with impaired fasting glucose or impaired glucose tolerance
11/08/2001	US20010039296 Method and composition for preventing or reducing the symptoms of menopause
11/08/2001	US20010039295 Transfusional iron overload
11/08/2001	US20010039294 11-beta-reductase inhibitor such as carbenoxolone to control 11-keto steroid conversion to 11-beta-hydroxysteroid; antidiabetic agents
11/08/2001	US20010039293 4((4-chloro-3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro -naphathalene-2-carbonyl)-amino)-2,6-difluoro-benzoic acid or its esters or salts used as agonists of alpha-retinoid receptors (=raralpha)
11/08/2001	US20010039291 1H-1,2,4-triazole derivtive
11/08/2001	US20010039290 Inhibit the release of inflammatory cytokines such as interleukin-1 and tumor necrosis factor from cells
11/08/2001	US20010039289 Antagonists; especially sodium salts
11/08/2001	US20010039287 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/08/2001	US20010039285 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
11/08/2001	US20010039284 Acetylcholine enhancers
11/08/2001	US20010039282 Desloratadine as non-sedating antihistamine, decongestant
11/08/2001	US20010039281 No drug resistance; intravenous
11/08/2001	US20010039280 Optically active 3-[(2-Piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT 1D receptor selective antagonists
11/08/2001	US20010039278 Anorectic and antidiabetic agents
11/08/2001	US20010039276 Phenethyl-thiourea compounds and use
11/08/2001	US20010039274 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
11/08/2001	US20010039273 Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
11/08/2001	US20010039272 Compounds activating pharmacological effect of retinoids
11/08/2001	US20010039271 For treatment of male erectile dysfunction, female sexual dysfunction
11/08/2001	US20010039268 New 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them
11/08/2001	US20010039265 Administering to the subject an effective amount of a polyglycoside or a salt thereof, wherein the polyglycoside comprises a chain of glycosidic residues substituted with an anionic substituent
11/08/2001	US20010039262 Methods and compositions for the treatment of cardiac indications
11/08/2001	US20010039261 Administration of polypeptide growth factors following central nervous system ischemia or trauma
11/08/2001	US20010039258 Exposing biologically active agent to complexing perturbant to reversibly transform biologically active agent to intermediate state and to form a subcutaneously deliverable supramolecular complex, subcutaneously administering complex
11/08/2001	US20010039257 Augmenting actions of cAMP in an effector system while reducing cAMP action in a nociceptive system comprising application of one or more forms of nitrogen oxide or carbon monoxide to a site wherein cAMP exists
11/08/2001	US20010039255 Use of alpha1A adrenoceptor agonists with alpha1B and alpha1D antagonism for the treatment of stress urinary incontinence
11/08/2001	US20010039041 Immunosuppressive sesbanimide compositions and methods of treatment using same
11/08/2001	US20010039038 Novel glucosaminidase
11/08/2001	US20010039017 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
11/08/2001	US20010039016 Measurement, calibration gene expression
11/08/2001	US20010039013 Screening, diagnosis cancer
11/08/2001	US20010038864 Extracting betulinic acid from the bark of plane tree with a solvent, inspissating the extracts, and recrystallizing the obtained betulinic acid; useful as anticancer agent and amides thereof as anti-HIV agents
11/08/2001	US20010038862 Administering drug and sodium hydroxide, for example to a localized region of a human patient's body surface to enhance the flux of the drug through the localized region without causing damage thereto
11/08/2001	US20010038861 Administering the drug to a localized region of a human patient's body in combination with sodium hydroxide for example to enhance flux without irritating
11/08/2001	US20010038860 As active ingredient a hydrophilic polymer mainly composed of monomeric units of alkylene glycols and/or vinyl monomeric units having a nondissociating hydrophilic group
11/08/2001	US20010038859 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity
11/08/2001	US20010038856 Hydromorphone therapy
11/08/2001	US20010038855 Dosage form for administering prescribed dose
11/08/2001	US20010038850 Method for preventing crystal formation in a dispersion of a liquid in a matrix
11/08/2001	US20010038849 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
11/08/2001	US20010038846 Applying glycolic acid to the keloid scar long enough to promote atrophy of the damaged skin; nontoxic, inexpensive
11/08/2001	US20010038838 Empiric treatment of infections potentially caused by drug resistance streptococcus pneumoniae in a human patient comprising the oral administration of a formulation comprising amoxycillin and potassium clavulanate
11/08/2001	US20010038831 Super-absorbent hydrogel foams
11/08/2001	US20010038830 N,O-amidomalonate platinum complexes
11/08/2001	US20010038827 Inhalation comprising an effective amount of a vesicant and a pharmeceutically acceptable carrier, wherein the vesicant does not exhibit substantial toxicity while treating a patient for neoplasm
11/08/2001	US20010038826 Inhalation comprising an effective amount of a vesicant and a pharmeceutically acceptable carrier, wherein the vesicant does not exhibit substantial toxicity while treating a patient for neoplasm
11/08/2001	US20010038825 Method and compositions for enhancing pulmonary function and treating pulmonary disorders
11/08/2001	EP1144348A3 Lta 4? hydrolase inhibitors
11/08/2001	EP1143938A3 Phinan
11/08/2001	DE10022077A1 Compositions for use as hair or skin cosmetics or as cleaning agents for e.g. glass, metals, plastics or leather contain 2-furanone derivatives
11/08/2001	DE10020935A1 Verwendung von Photofrin als Radiosensitizer Using Photofrin as a radiosensitizer
11/08/2001	DE10019755A1 New cyclic carboxylic acids are integrin antagonists, useful for treating inflammatory diseases, autoimmune and immune disorders, e.g. atherosclerosis, asthma and diabetes
11/08/2001	DE10018098A1 Treatment of cancer by apoptosis induction comprises administration of amino acid and saturated fatty acid derivatives
11/08/2001	CA2433897A1 Pharmaceutical formulation comprising carrier beads coated with a layer of valaciclovir
11/08/2001	CA2418748A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001	CA2409689A1 Combination therapy of respiratory diseases using antibodies
11/08/2001	CA2408073A1 Nucleic acids encoding a novel regulator of a g protein signaling, rgs18, and uses thereof
11/08/2001	CA2408011A1 Splice-region antisense composition and method
11/08/2001	CA2407965A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001	CA2407942A1 Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
11/08/2001	CA2407914A1 Use of benzamide derivatives for the treatment of high ocular tension and glaucoma
11/08/2001	CA2407824A1 Pharmaceutical composition
11/08/2001	CA2407808A1 Cyclipostins, process for their preparation and use thereof
11/08/2001	CA2407807A1 Stolonoxides
11/08/2001	CA2407799A1 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
11/08/2001	CA2407796A1 Cdk inhibitors having 3-hydroxychromen-4-one structure
11/08/2001	CA2407792A1 Ginsenoside chemotherapy
11/08/2001	CA2407713A1 A core formulation
11/08/2001	CA2407700A1 Compositions and methods for inducing activation of dendritic cells
11/08/2001	CA2407597A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001	CA2407594A1 Muscarinic agonists
11/08/2001	CA2407587A1 Ppar.gamma. modulators
11/08/2001	CA2407535A1 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
11/08/2001	CA2407418A1 Novel heterocyclic compounds with anti-inflammatory activity
11/08/2001	CA2407338A1 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
11/08/2001	CA2407337A1 A medicinal aerosol formulation
11/08/2001	CA2407334A1 Lipochroman-6 as no-synthase inhibitor and uses

1 ... 5972 5973 5974 5975 5976 5977 5978 5979 5980 5981 5982 5983 5984 5985 5986 5987 5988 5989 5990 5991 5992 ... 7860